Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Antares Pharma, Inc. (NASDAQ:ATRS) securities between December 21, 2016 and October 12, 2017 (the "Class Period"). Investors have until December 22, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Antares develops pharmaceutical delivery systems, distributes its needle-free injector systems in various countries, and conducts research and development with transdermal gel products. On December 21, 2016, Antares announced its submission of a New Drug Application ("NDA") for Xyosted to the U.S. Food and Drug Administration ("FDA"). Antares's product Xyosted has been among its lead product candidates throughout the Class Period. On October 11, 2017, the Company received a letter from the FDA, stating that the agency had "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for Xyosted. Following this news, Antares shares fell $1.41 per share, or over 37%, to close at $2.32 per share on October 13, 2017. On October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA regarding Xyosted's NDA. The Company stated that the FDA could not approve the NDA in its present form due to concerns that Xyosted "could cause a clinically meaningful increase in blood pressure" and also noted the FDA's concerns "regarding the occurrence of depression and suicidality." If you purchased or otherwise acquired Antares securities during the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Antares lawsuit, please go to www.bespc.com/atrs. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.